By Brad Sorensen, CFA
NASDAQ:TELO
READ THE FULL TELO RESEARCH REPORT
Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to reverse biological aging and degenerative diseases. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.”
Preclinical test results recently released further confirm the CEO’s statement and our belief in TELO. The company announced that a preclinical study showed that Telomir-1 restored mitochondrial function without triggering oxidative stress or cell proliferation in human cells derived from a patient with Hutchinson-Gilford Progeria Syndrome (HGPS). According to the company, Telomir-1 demonstrated a rare mitochondrial activity profile by selectively increasing mitochondrial energy production while simultaneously reducing reactive oxygen species (ROS). ROS is a damaging byproduct of oxidative metabolism. Importantly, and one of the major things that sets this treatment apart from other similar treatment is that this restoration occurred without causing the cells to divide, a key safety consideration in genetically unstable or disease-compromised cells. The potential implications of this finding are numerous, and the results may be relevant to other diseases where mitochondrial failure, oxidative stress, and limited regenerative capacity contribute to progression, including Parkinson’s disease, ALS (Amyotrophic Lateral Sclerosis), Alzheimer’s disease, Werner’s syndrome, and Progeria.
As with other conditions, Telomir-1 treats the underlying causes of progeria by regulating metal ions, reducing oxidative stress, restore mitochondrial function, extending telomere length, reversing muscle loss and resetting age-associated DNA methylation patterns. In contrast, the only current FDA-approved therapy for progeria, for example, has been shown to extend lifespan by an average of 4.3 years but does not reverse underlying disease pathology or halt cardiovascular decline—which remains the leading cause of death.
These results further indicate that Telomir-1 has the potential to reverse damage caused by a variety of aging-related conditions, which would be life-changing for millions of patients. Additionally, the company recently announced that it sold 1,100,000 shares of its common stock. Gross proceeds, according to the company, totaled approximately $2.9 million, prior to deducting fees and expenses. This is another move by company management that will allow the important preclinical testing to be concluded, and clinical trials begin.
Finally, the company also recently announced results from preclinical animal testing that further illustrate the tremendous potential that Telomir-1 has in reversing many of the worst conditions related to aging. The tests were done on an animal model of Wilson’s disease, which is a rare genetic disorder that can be fatal and is caused by mutation of genes that allow the body to eliminate excess copper. Patients suffering from this condition can experience inflammation, tissue damage, and multi-organ dysfunction.
In the trial, according to the company, Telomir-1 demonstrated the statistically significant reversal of major features of the disease, including:
- Up to a 4- to 5-fold reduction in episodic tremor events.
- Normalization of swim distance, swim velocity, and exploratory behavior.
- Reversal of ataxia-like motor behaviors (e.g., abnormal body bends and turn angles).
- Approximately 50% reduction in copper accumulation in dry liver tissue.
- Marked improvement in liver and kidney histopathology, with liver and kidney scores reduced to near-normal levels.
- Normalization of ALT, AST, and bilirubin—three critical liver biomarkers. ALT and AST are enzymes elevated during liver injury, while bilirubin builds up when detoxification is impaired. Telomir-1 restored these to wild-type levels, indicating protection of liver function and copper-induced damage.
These results continue the mounting evidence that Telomir-1 has the potential to have a major impact on the worst parts of the aging process, which would have an almost unlimited market potential. We continue to recommend investors take a look at TELO ahead of the human trials that are planned for early next year.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.